ClariVy Cervical IBF System Receives FDA Clearance

ClariVy Cervical IBF System: VySpine, a spine innovation leader using differentiated materials and designs, announced today that it has received 510(k) clearance from the FDA for the its ClariVy Cervical IBF System which is designed for use in anterior cervical discectomy with fusion (ACDF) procedures.

The ClariVy Cervical IBF System features cervical interbody fusion devices made from either PEEK Optima LT1, or PEEK Optima HA-Enhanced. PEEK Optima LT1 has been the standard for interbody devices for decades, featuring radiolucency and a modulus of elasticity close to that of natural bone. PEEK Optima HA-Enhanced has embedded Hydroxyapatite fibers to create better bony apposition to the implant.

“The ClariVy Cervical IBF System is the first in a series of differentiated interbody systems being developed by VySpine,” said Tom McLeer, CEO of VySpine. “Using new materials and creative surgeon input, we are building exceptional quality, flexibility, and pricing into all our products. This is just the next step in a series of exciting, innovative product launches scheduled for 2022.”

The ClariVy Cervical IBF System is offered in numerous footprints and heights, ranging from 4mm to 11mm and available either with or without locking screws. Additionally, the ClariVy implants are available in a range of lordosis. The ClariVy Cervical IBF System also features IBF-S implants, which have self-drilling screws to aid in anchoring the device directly to the bone. These screws are self-locking to ensure quick and easy fixation.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.